Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Oprozomib

Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle

DRUG

Sorafenib

Study subjects will receive sorafenib tablets twice a day for Days 1-28

Trial Locations (6)

Unknown

Lahey Hospital & Medical Center, Burlington

Rocky Mountain Cancer Centers, Denver

University of Miami Hospital & Clinics, Miami

The University of Chicago Medical Center, Chicago

The Ohio State University, Martha Morehouse Medical Plaza, Columbus

University of Wisconsin Comprehensive Cancer Center, Madison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY